BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 2469244)

  • 1. Prostate-specific antigen in management of prostatic carcinoma.
    Brawer MK; Lange PH
    Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
    Buamah PK; Johnson P; Skillen AW
    Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum prostate-specific antigen determination in prostatic carcinoma.
    Tizzani A; Casetta G; Piana P; Bellina M; Pecchio F; Aimo G; Adamo R
    Int J Biol Markers; 1987; 2(3):184-6. PubMed ID: 2453594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
    Guillet J; Role C; Duc AT; François H
    Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
    Csapo Z; Brand K; Walther R; Fokas K
    J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen. A review.
    Brawer MK
    Acta Oncol; 1991; 30(2):161-8. PubMed ID: 1709355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of prostatic acid phosphatase and prostatic specific antigen in the diagnosis of prostatic cancer.
    van Dalen A; Helmhout DH; van Caubergh RD
    Int J Biol Markers; 1988; 3(2):123-6. PubMed ID: 2468722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is acid phosphatase (PAP) still justified in the management of prostatic cancer?
    Kontturi M
    Acta Oncol; 1991; 30(2):169-70. PubMed ID: 1709356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
    Mulders TM; Bruning PF; Bonfrer JM
    Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
    van Dieijen-Visser MP; Hendriks MW; Delaere KP; Gijzen AH; Brombacher PJ
    Clin Chim Acta; 1988 Sep; 177(1):77-80. PubMed ID: 2460272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
    Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
    Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
    Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
    Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study on PAP, gamma-Sm and PA as tumor markers in prostatic cancer patients].
    Ohashi T; Akagi T; Irie S; Obama T; Nasu Y; Tohjoh S; Takeda K; Yoshimoto J; Matsumura Y; Ohmori H
    Nihon Hinyokika Gakkai Zasshi; 1987 Aug; 78(8):1403-8. PubMed ID: 2449560
    [No Abstract]   [Full Text] [Related]  

  • 18. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
    Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.
    van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ
    Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
    Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.